Videos

Kaitlin Mayne, MBChB, discusses an analysis of the EMPA-Kidney trial examining the effects of multimorbidity, polypharmacy, and quality of life on effects of empagliflozin.

Mona Shahriari, MD, discusses the evolving role of nonsteroidal topical options the management of plaque psoriasis.

Cindy X. Cai, MD, describes how both place and individual-level factors are associated with lapses in diabetic retinopathy care.

Ahead of the FDA decision on MDMA-assisted therapy to treat PTSD this summer, van der Kolk shares his thoughts on the logistics of care.

Van der Kolk discusses the long-term outlook of MDMA in patients with PTSD and what further outcomes he'd like to see explored in the space.

The FDA will decide on an application this summer for the treatment of PTSD with MDMA-assisted therapy. A renowned researcher explains how the treatment benefits patients with trauma.

At ARVO 2024, Dimitra Skondra, MD, describes the association between metformin use and decreased new-onset ICD coding of GA.

Robert Rosenson, MD, discusses the results of the ARCHES-2 trial and how it informs the potential of ANGPTL3 inhibition as well as RNAi therapies.

Julie Thomas, MS, DMSc, PA-C, discusses why ADHD cases may go undetected into adulthood, and the methods to treat such patients.

Deepak Sambhara, MD, describes the influence of baseline central retinal thickness on visual outcomes in a post-hoc analysis of the PHOTON study.

Ji Hyun “CJ” Chun, MPAS, PA-C, BC-ADM, explains how the adoption of 5 new diabetes subtypes may foster precision care.

Jonathan Barratt, MD, discusses a matching-adjusted indirect comparison of sparsentan and irbesartan against standard of care plus optimized RASI.

Helen Colhoun, MD, discusses the results of a SELECT analysis she presented at the 61st European Renal Association Congress.

Hear from Katharina Mayer, MD, and Georg Böhmig, MD, on the results of the phase 2 trial of felzartamab in patients with antibody-mediated rejection following kidney transplantation.

Sisson discusses the adoption of 2021 ATS / ERS guidelines, as well as the need for complementary testing and imagine to contextualize the full pulmonary patient.

Ji Hyun “CJ” Chun, MPAS, PA-C, BC-ADM, explains the potential value of defining diabetes subtypes based on insulin, obesity and age factors.

Sivers-Teixeira explains that while the care team should quickly expand once dementia has presented in screening, the primary care role stays consistent.

Ashley Malliett, DMSc, MPAS, PA-C, discusses the importance of timely diagnosis and initiated care, as well as contraindications for transplants and LVAD.

Aaron Henry, PA-C, MSHS, discusses why preventive care opportunities are often missed in Black men, and how community-based interventions may help.

Malliett discusses the signs that a caregiver should refer to an HF specialist for advanced care options, including LVAD and heart transplant.

Black men face significantly worse health outcomes in the US. Henry explains why the clinician needs to focus on building more authentic trust in their interactions.

These late-breaking data on drug candidate ENV-101 were presented at ATS 2024 and resulted from a new study on the drug’s effect on individuals with IPF.

James R. Kilgore, DMSc, PhD, PA-C, discusses a new primary care screening tool for cognitive decline, plus lifestyle interventions that may complement drugs.

Beth Browning, PA-C, LPC, provides advice for busy primary care providers to efficiently incorporate timely and treatment-initiating depression screening.

Fortman reviews the state of the 2021 AHA/ACC guideline recommendations to pursue shared decision making and cost-efficient testing strategies.

Kilgore reviews early cognitive decline tools include AD8 and MoCA, and how they should be utilized at the primary care level.

Bludorn reviews preventive measures and strategic collaboration to ensure high-risk patients for conditions like heat stroke are identified before an acute event occurs.

An AAPA 2024 session reflected on the joint AHA/ACC chest pain guidelines, particularly the adoption of high-density troponin level testing since 2021.